
Elisa Mandato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5957529/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 2020, 26, 1468-1479. | 30.7 | 87 |
| 2 | Targeted inhibition of PI3KÎ \pm /Î ^{r} is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood, 2019, 133, 70-80. | 1.4 | 75 |
| 3 | Protein Kinase CK2 Inhibition Down Modulates the NF-ήB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280. | 2.5 | 75 |
| 4 | Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia, 2017, 31, 292-300. | 7.2 | 55 |
| 5 | Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552. | 1.8 | 31 |
| 6 | Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene, 2016, 35, 6045-6052. | 5.9 | 24 |
| 7 | The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20. | 6.2 | 19 |
| 8 | Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Leukemia, 2014, 28, 2094-2097. | 7.2 | 14 |
| 9 | CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current Cancer Drug Targets, 2018, 18, 608-616. | 1.6 | 10 |
| 10 | Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL. Blood, 2018, 132, 39-39. | 1.4 | 0 |
| 11 | MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8. Blood, 2021, 138, 1324-1324. | 1.4 | 0 |
| 12 | Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 713-713. | 1.4 | 0 |